Welcome to our dedicated page for Incyte Genomics news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte Genomics stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz for FOP patients aged 12 and older on September 25, 2026.
The once-daily, 100 mg oral treatment is approved to reduce total new heterotopic ossification (HO) lesion volume, a measure of abnormal bone growth in soft tissue. Incyte developed Atebrioz and licensed worldwide development and commercialization to Mirum. In PROGRESS Cohort 1, mean total new HO lesion volume decreased by 3.2 cm3 with zilurgisertib, versus an increase of 24.6 cm3 with placebo at Week 24. Treatment effects were maintained through Week 48. Common adverse reactions included headache, joint pain, upper respiratory tract infection, nosebleeds and nausea. Atebrioz can cause fetal harm based on animal studies.
U.S. availability is expected in October through Mirum Access Plus, with eligible patients paying as little as $0 per month. The FDA issued Incyte a Rare Pediatric Disease Priority Review Voucher.
Incyte (INCY) will present new data from its inflammation and autoimmunity portfolio at the 2026 EADV Congress in Vienna, Austria.
Presentations span atopic dermatitis, hidradenitis suppurativa, prurigo nodularis and vitiligo, including multiple clinical and real‑world analyses of ruxolitinib cream (Opzelura) and Phase 3 data on the oral JAK1 inhibitor povorcitinib. Opzelura is already approved in the United States and Europe for certain patients with nonsegmental vitiligo and atopic dermatitis. Povorcitinib is in late‑stage development and has regulatory applications under review for moderate to severe hidradenitis suppurativa.
Specialised Therapeutics (ST) and Incyte (INCY) have expanded their partnership to commercialise, register and distribute ruxolitinib cream (Opzelura) in Australia, as announced on 20 September 2026.
Under the revised agreement, Incyte will continue to oversee development and manufacturing, while ST will manage local regulatory submissions, medical affairs, marketing and distribution. Ruxolitinib 1.5% cream is a topical Janus kinase (JAK) 1/2 inhibitor already approved in the United States and European Union for non-segmental vitiligo in patients 12 years and older and for certain patients with mild to moderate atopic dermatitis. ST described the deal as a key step into inflammatory dermatology and plans to progress Australian regulatory and reimbursement submissions for Opzelura in due course, with the goal of enabling equitable and timely patient access.
Incyte (Nasdaq: INCY) plans to present at three investor healthcare conferences in September 2026: the 21st Annual Wells Fargo Healthcare Conference on September 9 at 11:00 a.m. EDT, the Cantor Global Healthcare Conference 2026 on September 10 at 9:45 a.m. EDT, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16 at 12:20 p.m. EDT.
The presentations will be webcast live at Investor.Incyte.com and available for replay for 30 days.
Incyte (Nasdaq: INCY) granted inducement equity awards to 24 new employees under its 2024 Inducement Stock Incentive Plan. The grants, effective August 3, 2026, include RSUs for an aggregate 21,556 shares and stock options for 18,172 shares at an exercise price of $118.43 per share.
According to the company, RSUs vest in four annual 25% tranches, while options have a 10-year term and vest 25% after one year, with the balance vesting in 36 equal monthly installments, all subject to continued service and made in line with Nasdaq Listing Rule 5635(c)(4).
Specialised Therapeutics announced that Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is now listed on Australia’s Pharmaceutical Benefits Scheme (PBS) from 1 August 2026 for adults with relapsed or refractory follicular lymphoma (R/R FL, Grade 1–3a).
This is the first chemotherapy‑free, dual‑targeted CD19/CD20 immunotherapy regimen reimbursed on the PBS for these patients. The listing follows April 2026 TGA registration via Project Orbis and is enabled through Specialised Therapeutics’ exclusive 2021 distribution agreement with Incyte (NASDAQ: INCY) for Australia, New Zealand and Singapore.
In the Phase 3 inMIND trial, the Minjuvi combination reduced the risk of disease progression, relapse or death by 57% versus placebo plus rituximab and lenalidomide, with median progression‑free survival of 22.4 months vs 13.9 months (HR 0.43; P<0.0001). Safety was described as generally manageable but included high rates of infections and myelosuppression, requiring blood count monitoring and infection vigilance.
Incyte (Nasdaq: INCY) announced that the European Commission has approved Opzelura® (ruxolitinib) cream as the first steroid-free topical JAK inhibitor in the EU for adults with moderate atopic dermatitis whose disease is inadequately managed by, or unsuitable for, topical corticosteroids and topical calcineurin inhibitors.
The approval is based mainly on Phase 3b TRuE‑AD4 data, where Opzelura met both co-primary endpoints at Week 8: higher EASI-75 and IGA Treatment Success versus vehicle. Efficacy was maintained with as-needed dosing through Week 24, with EASI-75 in 84.3% and IGA-TS in 70.6% of patients, marked reductions in affected body surface area, and sustained itch and quality-of-life improvements. According to Incyte, Opzelura was well tolerated over 24 weeks with no serious infections, major cardiovascular events, malignancies or thromboses reported.
Incyte (Nasdaq: INCY) reported second quarter 2026 total revenue of $1.67 billion, up 38% year over year, with total net sales of $1.49 billion, up 40%. Excluding a one-time, non-cash Opzelura® benefit tied to a CMS agreement, total net sales grew 17%.
Jakafi®/Jakafi XR™ net sales were $817 million (+7%), Opzelura net sales $450 million (+173%; or $204 million, +24% excluding the one-time benefit), and the Hematology/Oncology portfolio reached $222 million (+69%). Cash, cash equivalents and marketable securities were $4.5 billion at June 30, 2026.
Incyte raised 2026 guidance for total net sales to $5.13–$5.26 billion, Opzelura to $1.05–$1.10 billion, and Hematology/Oncology to $860–$890 million, and increased GAAP operating expense guidance to $4.915–$4.995 billion, reflecting the $1.25 billion Vega Therapeutics acquisition and an estimated $1.27 billion IPR&D expense in Q3 2026.
Halozyme (Nasdaq: HALO) announced a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology.
According to Halozyme, it will receive an upfront payment from Incyte, plus potential milestone payments and royalties on net sales of medicines using ENHANZE®. Incyte also receives an option to nominate up to two additional targets for use with ENHANZE®.
Incyte (Nasdaq: INCY) will present new clinical data from its oncology portfolio in six sessions at the ESMO Congress 2026, held October 23-27, 2026, in Madrid. Four rapid oral presentations will feature Phase 1 data on INCB161734 (KRAS G12D inhibitor) in advanced/metastatic colorectal cancer and pancreatic ductal adenocarcinoma, INCA33890 (TGFβR2×PD-1 bispecific antibody) in microsatellite stable colorectal cancer, and INCB123667 (CDK2 inhibitor) with bevacizumab in recurrent epithelial ovarian cancer. Two poster presentations will cover final overall survival outcomes from the Phase 3 POD1UM-303/InterAACT-2 study of retifanlimab in first-line advanced squamous anal cancer and the Phase 3 MAESTRA 3 trial of INCB123667 with bevacizumab as first-line maintenance therapy in advanced epithelial ovarian-related cancers.